Translumina has announced the publication of 10-year clinical outcome data for its Yukon drug-eluting stent (DES) in patients with diabetes mellitus in the Journal of American Heart Association (JAHA).
The patients with diabetes mellitus present a particular challenge as the disease is associated with a more diffuse manifestation and consequently suboptimal clinical outcome after percutaneous coronary intervention (PCI). The device innovations have been focusing on improved polymer biocompatibility and different strategies to reduce the persistent inflammatory stimulus because of remaining polymer coating after completion of drug release.
“It is a moment of great pride for all of us at Translumina persisted to create this long-term safety and efficacy data with Yukon. Cardiologists world over now have a choice to give a proven drug-eluting stent to their diabetic patients who otherwise have poorer outcomes with conventional DES,” said Gurmit Singh Chugh, co-founder, Translumina.
In 2020, the Journal of the American College of Cardiology (JACC) published 10-year follow-up data on Translumina’s dual-drug polymer-free DES VIVO ISAR.
Previously, in 2018 10-year follow-up data on Yukon, in a head-to-head study against Xience (Abbott) from the ISAR-TEST 4 trial, were presented at the 2018 American Heart Association meeting and simultaneously published in Circulation.
“We are proud that Translumina is leading the global journey of creating the highest standard of clinical data that enables physicians to treat patients with more confidence and certainty,” said Arjun Oberoi, managing director, Everstone Capital, Singapore, which invested in Translumina in 2019.